Dacomitinib as first-line treatment for patients with EGFR-mutant non-small- cell lung cancer: Real-world data and Insights

Dacomitinib as first-line treatment for patients with EGFR-mutant non-small- cell lung cancer: Real-world data and Insights | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Dacomitinib as first-line treatment for patients with EGFR-mutant non-small- cell lung cancer: Real-world data and Insights Ji Eun Shin, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4671317/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 07 Feb, 2025 Read the published version in Scientific Reports → Version 1 posted 10 You are reading this latest preprint version Abstract Dacomitinib demonstrated superior survival benefit compared to gefitinib as a first-line treatment in non-small cell lung cancer (NSCLC) patients with common EGFR mutations through ARCHER 1050. However, there is limited real-world data concerning its efficacy and safety. This study included patients with EGFR-mutant NSCLC who received dacomitinib as a first-line treatment between January 2021 and December 2022 at Samsung Medical Center and St. Vincent’s Hospital. This study assessed the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), safety profile of dacomitinib, and subsequent treatments after dacomitinib failure. In total, 153 patients were included in this study. Exon 19 deletion was observed in 50.3% of patients, while the L858R mutation in exon 21 was observed in 46.4% of patients. 45.1% of patients had brain metastasis. The ORR was 84.3%. The median follow-up duration was 16.9 months, with a median PFS of 16.7 months (95% CI, 14.4 to 25.2). Based on the type of EGFR mutation, the median PFS was 18.1 months (95% CI, 14.5 to NE) in patients with exon 19 deletion, and 15.9 months (95% CI, 12.5 to NE) in patients with L858R mutation. Grade 3 or higher adverse events were observed in 7.2% of patients. Initially administered at a dose of 45 mg, dose reduction was necessary for 85.6% of patients, with a final dosage of 30 mg in 49.0% and 15 mg in 36.6% of cases. Out of the 60 patients who experienced disease progression, 31 underwent tissue re-biopsy and 25 underwent liquid biopsy. Overall, T790M mutation was detected in 40.9% of patients who progressed after dacomitinib. The survival benefit of dacomitinib has been demonstrated, indicating its promising efficacy in a real-world setting. The detection rate of the T790M mutation after dacomitinib treatment failure was comparable to that of other second-generation EGFR-TKIs. Biological sciences/Cancer/Lung cancer Health sciences/Oncology/Cancer/Cancer therapy Epidermal growth factor receptor (EGFR) mutant Non-small cell lung cancer (NSCLC) Dacomitinib Real-world data Figures Figure 1 Figure 2 Figure 3 Introduction Lung cancer remains the leading cause of cancer-related death 1 , with non-small cell lung cancer (NSCLC) constituting nearly 85% of newly diagnosed cases. Over the last decade, significant progress has occurred in the understanding of NSCLC. Targeted therapy has notably enhanced clinical outcomes for a considerable portion of advanced/metastatic NSCLC patients possessing actionable genetic alterations, particularly Epidermal Growth Factor Receptor (EGFR) mutations 2 . Among these, EGFR mutation is the most common targetable driver mutation in lung cancer, appearing in 17%-61% of NSCLC adenocarcinomas, with higher frequencies observed in Asian, female, and never-smoker patients 3 . The most common EGFR mutations include exon 19 deletion and L858R mutation in exon 21 and are observed in 80–90% of cases 4 . First-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib, and second-generation TKIs like afatinib and dacomitinib have previously demonstrated clinical superiority over platinum-based chemotherapy 5 – 8 . Recently, osimertinib (third-generation EGFR-TKI) has emerged as the preferred first-line option, showing enhanced survival benefits compared with first-generation EGFR-TKIs 9 . Dacomitinib is an orally administered, small-molecule irreversible TKI that targets HER1 (EGFR), HER2, and HER4 10 . Two distinguishing features of this second-generation EGFR TKI, which distinguish them from first-generation EGFR TKIs, are their irreversible mode of binding and their broader activity against HER family members 11 . ARCHER 1050 aimed to compare the efficacy and safety of dacomitinib with gefitinib (first-generation EGFR-TKI) for the first-line treatment of locally advanced/metastatic NSCLC with common EGFR mutations. Dacomitinib demonstrates superior efficacy in progression-free survival (PFS) and overall survival (OS) compared to gefitinib with a median PFS of 14.7 months versus 9.2 months (hazard ratio 0.59, p < 0.0001) and a median OS of 34.1 months versus 26.8 months (hazard ratio 0.76, p = 0.044) 8 . Based on the result of ARCHER 1050, dacomitinib obtained FDA approval as a first-line treatment for patients with metastatic NSCLC with EGFR exon 19 deletion or L858R mutation in exon 21. However, there is relatively limited real-world data available regarding its efficacy and safety. In particular, a significant limitation of ARCHER 1050 is the exclusion of patients with brain metastasis, which results in a gap in the evidence concerning survival benefits in this subgroup of patients. Hence, real-world data are required to address this issue. Furthermore, there is limited understanding of acquired resistance mechanism and available subsequent treatment options when the disease progresses following dacomitinib as a first-line treatment in the clinical setting. This multi-center retrospective study aims to clarify the efficacy and safety of dacomitinib as a first-line treatment for patients with EGFR-mutant NSCLC. Additionally, it explores subsequent treatment strategies following dacomitinib failure in a real-world setting. Results Study population and clinical characteristics Between January 6th, 2021, and December 9th, 2022, 153 patients received dacomitinib as a first-line treatment. Table 1 shows the baseline characteristics of study population. The median age at diagnosis was 64.6 years. Among total, 60.8% were female, and 68.6% were never-smokers. One hundred and forty-seven patients (96.1%) had adenocarcinoma, while 6 patients had other pathologies. Ninety-nine patients (64.7%) were diagnosed with stage IV at the time of diagnosis, with 47 patients (30.7%) undergoing surgery and 10 patients (6.5%) receiving definitive concurrent chemoradiotherapy, and experiencing progression to primary therapy. Exon 19 deletions were observed in 77 patients (50.3%), and 71 (46.4%) had L858R mutations in exon 21. Table 1 Baseline chacteristics. a The histology of the 3 patients were adeno-squamous. b The EGFR mutation status of patients categorized under others is as follows: L861Q mutation in exon 21, Exon 20 insertion, G719X mutation in exon 18, G719X mutation in exon 18 and S768I mutation in exon 20, G719X mutation in exon 18 and L861Q mutation in exon 21. ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; CCRT, concurrent chemo-radiotherapy. Patient Characteristics Number of patients (%) Age (years), median (range) 64.6 (54.5–74.7) < 65 years 79 (51.6%) ≥ 65 years 74 (48.4%) Sex Male 60 (39.2%) Female 93 (60.8%) ECOG performance status 0 47 (30.7%) 1 100 (65.4%) ≥ 2 6 (4.0%) Smoking status Never smoker 105 (68.6%) Current or Ex-smoker 48 (31.4%) Histology Adenocarcinoma 147 (96.1%) Squamous 3 (2.0%) Others a 3 (2.0%) Stage at initial diagnosis I 23 (15.0%) II 12 (7.9%) III 19 (12.4%) IV 99 (64.7%) Previous history of treatments Curative surgery 47 (30.7%) Definitive CCRT 10 (6.5%) Type of EGFR mutation Exon 19 deletion 77 (50.3%) L858R mutation in exon 21 71 (46.4%) Others b 5 (3.3%) Distant metastasis at initiation of dacomitinib Brain 69 (45.1%) Bone 56 (36.6%) Pleura 45 (29.4%) Adrenal gland 10 (6.5%) Liver 7 (4.6%) At the initiation of dacomitinib, 69 patients (45.1%) presented with concurrent brain metastasis, while bone metastasis, pleural metastasis, liver metastasis, and adrenal metastasis were observed in 56 (36.6%), 45 (29.4%), 10 (6.5%), and 7 (4.6%) patients, respectively. Efficacy of dacomitinib The data lock was performed on April 30th, 2023. At the time of data lock, with 16.9 months of median follow-up duration (range: 5.9–27.9), 67 patients experienced a PFS event, while 73 patients continued dacomitinib. The median number of cycles of dacomitinib was 13 (range: 2–24). Out of the 153 patients receiving dacomitinib, one patient achieved CR (0.7%), while 128 achieved PR (83.7%), resulting in an ORR of 84.3% (Table 2 ). The median PFS was 16.7 months (95% CI; 14.4–25.2) in total population (Fig. 1 A). The median OS was not reached, with a 24-month OS rate of 83.9% (Fig. 1 B). Among patients with exon 19 deletion, the median PFS was 18.1 months (95% CI: 14.5–not reached), while among those with the L858R mutation in exon 21, the median PFS was 15.9 months (95% CI: 12.5–not reached) (Fig. 2 A). Among patients with brain metastasis, the median PFS was 14.5 months (95% CI: 11.2–20.0), whereas the median PFS was 20.2 months in those without brain metastasis (95% CI: 17.5–not reached), indicating a longer PFS in the absence of brain metastasis ( p = 0.037) (Fig. 2 B). Table 2 Objective response to dacomitinib. PFS, Progression-free survival. Treatment response Number of patients (%) No. of cycles, median (range) 13 (2–24) Complete response 1 (0.7%) Partial response 128 (83.7%) Stable disease 11 (7.2%) Progressive disease 6 (3.9%) Unknown 7 (4.6%) Overall objective response rate 129 (84.3%) Overall disease control rate 140 (91.5%) Proportion overall PFS at 12 months 48.4% Safety profile Out of the total 153 patients, 94.1% reported at least one adverse event, while 11 patients (7.2%) reported adverse events of grade 3 or higher. Grade 4 adverse event was not reported. The most commonly reported adverse events were rash, diarrhea, and mucositis (51.0%, 49.0%, and 40.5% respectively) (Table 3 ). Table 3 Adverse events and dose reduction of dacomitinib. Adverse Events Any grade Grade ≥ 3 Diarrhea 75 (49.0%) 3 (2.0%) Paronychia 60 (39.2%) 0 (0.0%) Dermatitis 45 (29.4%) 1 (0.7%) Rash 78 (51.0%) 7 (4.6%) Oral mucositis 62 (40.5%) 0 (0.0%) Nausea 3 (2.0%) 0 (0.0%) Fatigue 6 (3.9%) 0 (0.0%) Increased AST/ALT 1 (0.7%) 0 (0.0%) Pneumonitis 0 (0.0%) 0 (0.0%) Final reduced dose owing to adverse events No dose reduction 22 (14.4%) Dose reduction 131 (85.6%) 30 mg per day 75 (49.0%) 15 mg per day 56 (36.6%) Permanent discontinuation 13 (8.5%) Temporary interruption 37 (24.2%) One hundred and fifty patients started on a once-daily dose of 45 mg of dacomitinib, while three patients started dacomitinib with a dosage of 30 mg. Dose reductions owing to adverse events occurred in 131 (85.6%) patients. The lowest dacomitinib dose was 30 mg once daily in 75 patients (49.0%) and 15 mg once daily in 56 patients (36.6%). Moreover, it took a median time of 1.2 months to achieve a dose reduction of 30 mg, and 4.3 months to 15 mg. Temporary dose interruptions occurred in 37 (24.2%) patients. Thirteen patients (8.5%) permanently discontinued dacomitinib and changed to other EGFR-TKI owing to intolerable adverse events. Subsequential treatment after dacomitinib Figure 3 summarizes the subsequent treatments of patients after dacomitinib as a first-line treatment. Seventy-three patients continued dacomitinib without evidence of disease progression, while 14 patients discontinued dacomitinib for reasons other than disease progression. Among 66 patients who experienced disease progression while on dacomitinib, 22 patients (33.3%) continued dacomitinib under the concept of beyond progression. Among them, lesions associated with disease progression occurred in the brain, bone, and lung in 11, 9, and 3 patients, respectively. Among 11 patients with intracranial progression, 8 patients underwent gamma-knife radiosurgery for the corresponding lesions. At the time of data lock, 6 patients continued dacomitinib beyond disease progression. Thirty-one patients underwent tissue re-biopsy to confirm the acquired resistance mechanism of dacomitinib. Nine patients had the EGFR T790M mutation in exon 20 (T790M), and all of them switched to third-generation EGFR TKIs: 2 patients to osimertinib and 7 to lazertinib. Additional liquid biopsy was performed in 18 patients who did not have T790M on tissue re-biopsy. Three patients had T790M and two of them switched to third-generation EGFR TKIs: 1 to osimertinib and 1 to lazertinib. Fifteen patients were without the T790M mutation either by tissue re-biopsy or liquid biopsy. Three of them were enrolled in a clinical trial for further treatment and remain under observation, while 11 patients received platinum-based cytotoxic chemotherapy (10 received pemetrexed/carboplatin and 1 received gemcitabine/carboplatin). One patient refused further treatment owing to poor performance status. Liquid biopsy was performed in 25 patients among patients who did not receive tissue re-biopsy. Fifteen patients had T790M and all of them switched to third-generation EGFR TKI; 8 to osimertinib and 7 to lazertinib. Among 12 patients who did not have T790M, 5 patients received cytotoxic chemotherapy (4 received pemetrexed/Carboplatin and 1 received gemcitabine/carboplatin). Others refused further treatment owing to poor performance or were transferred to another hospital. Overall, T790M was detected in 40.9% of patients who progressed from dacomitinib. In patients who underwent tissue re-biopsy, additional examinations were conducted to identify other resistance mechanisms beyond T790M. C-MET expression was assessed through immunohistochemistry staining using re-biopsy tissue, with positive results observed in 7 patients. No histological transformation to small-cell lung cancer was detected. Additionally, next-generation sequencing (NGS) was conducted in 11 patients, and TP53 mutation was detected in 8 of them. Discussion In this retrospective study, dacomitinib showed a durable efficacy and maintained a manageable safety profile but necessitated dose reduction in the majority of patients in patients with EGFR-mutated NSCLC. For the overall population, ORR was 84.3% and the median PFS was 16.7 months, which was quite superior to the survival results represented in ARCHER 1050 8 . The primary differences in baseline characteristics compared to ARCHER 1050 are the presence of brain metastasis and racial composition. Unlike ARCHER 1050, which demonstrated a relatively diverse racial distribution with 75% Asian, 25% White, and less than 1% Black participants, this retrospective study was only included Asian in South Korea. Furthermore, ARCHER 1050 excluded patients with brain metastasis, while 45.1% of patients had brain metastasis at the initiation of dacomitinib in this study. Survival results are superior in this study compared to ARCHER 1050, despite including patients with brain metastasis. The distribution of smoking status and the prevalence of EGFR mutation, including exon 19 deletion and L858R mutation in exon 21 were comparable between this study and ARCHER 1050. As mentioned above, the efficacy of dacomitinib in patients with brain metastasis was initially unclear in previous prospective studies. In this study, the inclusion of patients with brain metastasis and survival analysis based on the presence of brain metastasis contributed to obtaining insight regarding this aspect, despite its retrospective nature. The median PFS was 16.7 months despite 45.1% of patients having brain metastasis. Several retrospective studies showed the intracranial efficacy of dacomitinib, with an overall intracranial objective response rate (iORR) of 85% 12,13 . In a previous prospective study involving 30 patients with brain metastasis, dacomitinib demonstrated an iORR of 96.7% and the median PFS was 17.5 months 14 . In subgroup analysis conducted based on EGFR mutation in ARCHER 1050, dacomitinib demonstrated significantly superior survival efficacy compared to gefitinib in patients harboring L858R mutation in exon 21 (hazard ratio: 0.63, 95% CI; 0.44–0.88). The superior survival efficacy of dacomitinib in patients with the L858R mutation in exon 21 represents a unique feature not observed in other EGFR-TKIs, including afatinib, which belongs to the same generation of EGFR TKIs 7 . Recent in vitro studies revealed that dacomitinib demonstrates the lowest IC50 values for the L858R mutation in exon 21 (IC50 = 2.6) compared to gefitinib (IC50 = 26), erlotinib (IC50 = 16), afatinib (IC50 = 4), and osimertinib (IC50 = 9). The efficacy of dacomitinib in L858R mutation in exon 21 appears to be linked to these IC50 values 15 . Additionally, in FLAURA, subgroup analysis based on EGFR mutation demonstrates relatively limited OS benefit in L858R mutation in the exon 21 subgroup with osimertinib (hazard ratio: 1.0, 95% CI; 0.71–1.40) 16 . Dacomitinib may represent a promising treatment option for patients with EGFR-mutant NSCLC harboring L858R mutation in exon 21, when compared to other EGFR TKIs. The recommended optimal starting dose for dacomitinib is 45 mg per day in ARCHER 1050. However, women, Asians, and patients with lower body weight tend to reduce the dose 17 . In this study, dose reductions were necessary in most patients (85.6%) owing to adverse events. This study also showed that the reduction to 30 mg took a median time of 1.2 months, while further reduction to 15 mg required a median time of 4.3 months. The relatively early implementation of dose reductions can be attributed to the prevailing belief that a generous reduction is preferable and does not compromise efficacy 17 . The metabolism of dacomitinib varies individually. In previous study of dacomitinib through plasma concentration, there was no difference among the patients who remained on 45 mg per day, those who had their dose reduced from 45 mg to 30 mg per day, and those who had their dose reduced from 45 mg to 30 mg and then to 15 mg per day. Starting at 45 mg or 30 mg per day and adjusting according to adverse events with close and frequent follow-up is a top-down approach which considered to be optimal 17 . It is well-established that T790M mutation in exon 20 occur in 50%-60% of patients treated with EGFR first- or second-generation TKIs 18 . The clinical data regarding the resistance mechanism of dacomitinib is still limited. In this study, T790M mutations were observed in 40% of cases, which is consistent with previous data from other first- or second-generation EGFR-TKIs. This study had several limitations. The median OS was not reached owing to the relatively short follow-up time. Additionally, the retrospective nature of this study and the small sample size further constrain its findings. In conclusion, this study demonstrated a real-world efficacy of dacomitinib in EGFR-mutated NSCLC as a first-line treatment. With a tolerable safety profile and superior survival efficacy compared with previous prospective studies, it is anticipated to be a valuable second-generation EGFR TKI in clinical practice. Additionally, the study highlights its efficacy in patients with brain metastasis, establishing it as one of the viable treatment options for NSCLC patients with brain metastasis. Patients and Methods Study participants and study procedure This study included patients with advanced/metastatic EGFR-mutant NSCLC who were administered first-line dacomitinib between January 6th, 2021, and December 9th, 2022 at Samsung Medical Center and St. Vincent’s Hospital. All patients received a dosage of 45 mg of dacomitinib administered once daily in 28-day cycles until they experienced objective disease progression, unacceptable toxicity, or death. A dose reduction to 30 mg or 15 mg was performed when patients experienced grade 2 or higher treatment-related toxicities. We reviewed the electronic clinical records and extracted data on age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, smoking status, stage at initial diagnosis, histopathology, type of EGFR mutation, and distant metastasis at initiation of dacomitinib. This study was approved by the Institutional Review Board of the Samsung Medical Center with a waiver for informed consent (Institutional Review Board no. 2023-05-039). Study endpoints and statistical analysis Tumor response was evaluated as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Objective response rate (ORR) was defined as the percentage (%) of patients with confirmed CR or PR. PFS was measured from the start of dacomitinib to the date of disease progression using RECIST 1.1 or death from any cause. OS was calculated from the start of dacomitinib to the date of death from any cause. The safety objectives were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.3. The categorical and continuous variables were summarized using descriptive statistics. The survival analysis was performed using Kaplan-Meier curves and compared using a log-rank test. All p-values were two-sided and confidence intervals (CI) were at the 95% level, with statistical significance defined as p ≤ 0.05. All statistical analyses were performed using IBM SPSS Statistics 27 and R version 4.3.3. Declarations Competing Interests The author(s) declare no competing interests. Ethic declarations This study was conducted in accordance with the ethical principles of the Declaration of Helsinki (as revised in 2013). This study was approved by the Institutional Review Board at Samsung Medical Center (IRB No. 2023-05-039), and individual consent for this retrospective analysis was waived. Author Contribution The conception and design of the study were carried out by JE Shin, HA Jung, and BY Shim. Administrative support for the study was provided by BY Shim. The study materials or patients were provided by all the authors. The collection and assembly of data were performed by JE Shin and HA Jung. Data analysis and interpretation were conducted by JE Shin and HA Jung. All authors contributed to the writing of the manuscript. The final approval of the manuscript was given by all the authors. Acknowledgement This was an independent, investigator-initiated study supported by Pfizer. Data availability The data analyzed in this study are Samsung Medical center and St. Vincent’s Hospital. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors upon reasonable request with the permission of Samsung Medical center and St. Vincent’s Hospital. References Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 71, 7–33. http://doi.org/10.3322/caac.21654 (2021). Alexander, M., Kim, S. Y. & Cheng, H. Update 2020: Management of Non-Small Cell Lung Cancer. Lung 198, 897–907. http://doi.org/10.1007/s00408-020-00407-5 (2020). Kawaguchi, T. et al. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. J. Clin. Oncol. 34, 2247–2257. http://doi.org/10.1200/JCO.2015.64.2322 (2016). Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S. & Halmos, B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1, 497–514. http://doi.org/10.18632/oncotarget.186 (2010). Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957. http://doi.org/10.1056/NEJMoa0810699 (2009). Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246. 10.1016/S1470-2045(11)70393-X (2012). Park, K. et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17, 577–589. http://doi.org/10.1016/S1470-2045(16)30033-X (2016). Wu, Y. L. et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 1454–1466. http://doi.org/10.1016/S1470-2045(17)30608-3 (2017). Soria, J. C. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 378, 113–125. http://doi.org/10.1056/NEJMoa1713137 (2018). Shirley, M. Dacomitinib: First Global Approval. Drugs 78, 1947–1953. http://doi.org/10.1007/s40265-018-1028-x (2018). Yu, H. A. & Riely, G. J. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J. Natl. Compr. Canc. Netw. 11, 161–169. http://doi.org/10.6004/jnccn.2013.0024 (2013). Peng, W. et al. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report. Lung Cancer 152, 66–70. http://doi.org/10.1016/j.lungcan.2020.12.008 (2021). Zhang, J. et al. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. Thorac. Cancer 12, 3407–3415. http://doi.org/10.1111/1759-7714.14222 (2021). Jung, H. A. et al. Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study. ESMO Open 8, 102068. http://doi.org/10.1016/j.esmoop.2023.102068 (2023). Kobayashi, Y. & Mitsudomi, T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 107, 1179–1186. http://doi.org/10.1111/cas.12996 (2016). Ramalingam, S. S. et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N. Engl. J. Med. 382, 41–50. http://doi.org/10.1056/NEJMoa1913662 (2020). Corral, J. et al. Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 15, 2795–2805. http://doi.org/10.2217/fon-2019-0299 (2019). Tan, A. C. & Tan, D. S. W. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J. Clin. Oncol. 40, 611–625. http://doi.org/10.1200/JCO.21.01626 (2022). Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 07 Feb, 2025 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Revision requested 25 Sep, 2024 Reviews received at journal 23 Sep, 2024 Reviewers agreed at journal 18 Sep, 2024 Reviews received at journal 10 Aug, 2024 Reviewers agreed at journal 09 Aug, 2024 Reviewers invited by journal 04 Jul, 2024 Editor assigned by journal 04 Jul, 2024 Editor invited by journal 04 Jul, 2024 Submission checks completed at journal 04 Jul, 2024 First submitted to journal 02 Jul, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4671317","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":331178701,"identity":"387cb7f3-fe93-4cda-8bce-60dcfbf68d14","order_by":0,"name":"Ji Eun Shin","email":"","orcid":"","institution":"St. Vincent’s Hospital, The Catholic University of Korea","correspondingAuthor":false,"prefix":"","firstName":"Ji","middleName":"Eun","lastName":"Shin","suffix":""},{"id":331178702,"identity":"d3375709-b013-4359-ad2a-08e9ff2034ce","order_by":1,"name":"Hyun Ae Jung","email":"","orcid":"","institution":"Samsung Medical Center, Sungkyunkwan University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Hyun","middleName":"Ae","lastName":"Jung","suffix":""},{"id":331178705,"identity":"8a776ca1-15ec-4330-8a7a-ae69a28ef17d","order_by":2,"name":"Sehhoon Park","email":"","orcid":"","institution":"Samsung Medical Center, Sungkyunkwan University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Sehhoon","middleName":"","lastName":"Park","suffix":""},{"id":331178707,"identity":"e1cb1d7c-bb09-44f6-b2e5-8f53c921d497","order_by":3,"name":"Jong-Mu Sun","email":"","orcid":"","institution":"Samsung Medical Center, Sungkyunkwan University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Jong-Mu","middleName":"","lastName":"Sun","suffix":""},{"id":331178709,"identity":"4f24a5ad-cabf-42e9-bc1f-cc2c7e7028c1","order_by":4,"name":"Se-Hoon Lee","email":"","orcid":"","institution":"Samsung Medical Center, Sungkyunkwan University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Se-Hoon","middleName":"","lastName":"Lee","suffix":""},{"id":331178710,"identity":"a6987431-11bb-493a-8088-ccac0a4e9fc9","order_by":5,"name":"Jin Seok Ahn","email":"","orcid":"","institution":"Samsung Medical Center, Sungkyunkwan University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Jin","middleName":"Seok","lastName":"Ahn","suffix":""},{"id":331178712,"identity":"34a1f36c-f9db-489b-b580-c6d8b91c47a5","order_by":6,"name":"Myung-Ju Ahn","email":"","orcid":"","institution":"Samsung Medical Center, Sungkyunkwan University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Myung-Ju","middleName":"","lastName":"Ahn","suffix":""},{"id":331178713,"identity":"04815ec0-0f46-4edc-a14a-6c1027ed1dde","order_by":7,"name":"Byoung Yong Shim","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA5UlEQVRIie3RMQrCMBSA4VcCnaqudWmukCA4Sc+SUtDFoS7iWBDj5F5x8AziBVoKdSl1LcShk7MH6GBaFLfYUTD/9Aj54IUA6HS/mG2ECGAiJwugIu0Z6kKmAKYkrBtpb6QvAh0IPqw35wW/4sFxl1QscGGwjdFopSDklnCx54JGWd8njPhg5wx5uYrYHhc9Lhhk1thmJAYoASWharGoJQXDb4K/EShbEjPyJkQST0VIQ6LCp6dsPmreYtHcW1P1YrO7CJYudtKcVo/adZxLmg6VizUZ5meWv2N8BbK6wx2dTqf7356mPkyRwd3XGQAAAABJRU5ErkJggg==","orcid":"","institution":"St. Vincent’s Hospital, The Catholic University of Korea","correspondingAuthor":true,"prefix":"","firstName":"Byoung","middleName":"Yong","lastName":"Shim","suffix":""}],"badges":[],"createdAt":"2024-07-02 04:21:20","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4671317/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4671317/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-024-81704-4","type":"published","date":"2025-02-07T15:57:22+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":61358158,"identity":"cc63934a-cc2d-4c01-941d-8b17dc9d2431","added_by":"auto","created_at":"2024-07-29 21:17:09","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":24006,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan–Meier curve of (A) progression-free survival and (B) overall survival\u003cstrong\u003e.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-4671317/v1/e329e83d28b0a37deb7dc3c3.png"},{"id":61357211,"identity":"8a45e4d3-ea41-4edf-9c07-f1515a6bbb30","added_by":"auto","created_at":"2024-07-29 21:09:09","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":34883,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan–Meier curves of progression-free survival according to (A) the type of EGFR mutation (exon19 deletion and L858R mutation in exon 21) and (B) the presence of brain metastasis.\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-4671317/v1/b2720e324cbf53c99276e612.png"},{"id":61357213,"identity":"e215120d-04cd-47af-a11b-d21a699f275c","added_by":"auto","created_at":"2024-07-29 21:09:09","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":837421,"visible":true,"origin":"","legend":"\u003cp\u003eFlow chart of subsequent treatments.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-4671317/v1/b3e0a1780b2f826281b9098e.png"},{"id":75930378,"identity":"f1ab0375-9c4a-4d94-8dfc-bccd0c773ba9","added_by":"auto","created_at":"2025-02-10 16:10:46","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1446633,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4671317/v1/d4b2e32c-ffef-41b2-b8ba-010f15e2a31c.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Dacomitinib as first-line treatment for patients with EGFR-mutant non-small- cell lung cancer: Real-world data and Insights","fulltext":[{"header":"Introduction","content":"\u003cp\u003eLung cancer remains the leading cause of cancer-related death\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e, with non-small cell lung cancer (NSCLC) constituting nearly 85% of newly diagnosed cases. Over the last decade, significant progress has occurred in the understanding of NSCLC. Targeted therapy has notably enhanced clinical outcomes for a considerable portion of advanced/metastatic NSCLC patients possessing actionable genetic alterations, particularly Epidermal Growth Factor Receptor (EGFR) mutations\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Among these, EGFR mutation is the most common targetable driver mutation in lung cancer, appearing in 17%-61% of NSCLC adenocarcinomas, with higher frequencies observed in Asian, female, and never-smoker patients\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. The most common EGFR mutations include exon 19 deletion and L858R mutation in exon 21 and are observed in 80\u0026ndash;90% of cases\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. First-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib, and second-generation TKIs like afatinib and dacomitinib have previously demonstrated clinical superiority over platinum-based chemotherapy\u003csup\u003e\u003cspan additionalcitationids=\"CR6 CR7\" citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Recently, osimertinib (third-generation EGFR-TKI) has emerged as the preferred first-line option, showing enhanced survival benefits compared with first-generation EGFR-TKIs\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eDacomitinib is an orally administered, small-molecule irreversible TKI that targets HER1 (EGFR), HER2, and HER4\u003csup\u003e10\u003c/sup\u003e. Two distinguishing features of this second-generation EGFR TKI, which distinguish them from first-generation EGFR TKIs, are their irreversible mode of binding and their broader activity against HER family members\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. ARCHER 1050 aimed to compare the efficacy and safety of dacomitinib with gefitinib (first-generation EGFR-TKI) for the first-line treatment of locally advanced/metastatic NSCLC with common EGFR mutations. Dacomitinib demonstrates superior efficacy in progression-free survival (PFS) and overall survival (OS) compared to gefitinib with a median PFS of 14.7 months versus 9.2 months (hazard ratio 0.59, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and a median OS of 34.1 months versus 26.8 months (hazard ratio 0.76, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.044)\u003csup\u003e8\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eBased on the result of ARCHER 1050, dacomitinib obtained FDA approval as a first-line treatment for patients with metastatic NSCLC with EGFR exon 19 deletion or L858R mutation in exon 21. However, there is relatively limited real-world data available regarding its efficacy and safety. In particular, a significant limitation of ARCHER 1050 is the exclusion of patients with brain metastasis, which results in a gap in the evidence concerning survival benefits in this subgroup of patients. Hence, real-world data are required to address this issue. Furthermore, there is limited understanding of acquired resistance mechanism and available subsequent treatment options when the disease progresses following dacomitinib as a first-line treatment in the clinical setting.\u003c/p\u003e \u003cp\u003eThis multi-center retrospective study aims to clarify the efficacy and safety of dacomitinib as a first-line treatment for patients with EGFR-mutant NSCLC. Additionally, it explores subsequent treatment strategies following dacomitinib failure in a real-world setting.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy population and clinical characteristics\u003c/h2\u003e \u003cp\u003eBetween January 6th, 2021, and December 9th, 2022, 153 patients received dacomitinib as a first-line treatment. Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e shows the baseline characteristics of study population. The median age at diagnosis was 64.6 years. Among total, 60.8% were female, and 68.6% were never-smokers. One hundred and forty-seven patients (96.1%) had adenocarcinoma, while 6 patients had other pathologies. Ninety-nine patients (64.7%) were diagnosed with stage IV at the time of diagnosis, with 47 patients (30.7%) undergoing surgery and 10 patients (6.5%) receiving definitive concurrent chemoradiotherapy, and experiencing progression to primary therapy. Exon 19 deletions were observed in 77 patients (50.3%), and 71 (46.4%) had L858R mutations in exon 21.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline chacteristics. \u003csup\u003ea\u003c/sup\u003eThe histology of the 3 patients were adeno-squamous. \u003csup\u003eb\u003c/sup\u003eThe EGFR mutation status of patients categorized under others is as follows: L861Q mutation in exon 21, Exon 20 insertion, G719X mutation in exon 18, G719X mutation in exon 18 and S768I mutation in exon 20, G719X mutation in exon 18 and L861Q mutation in exon 21. ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; CCRT, concurrent chemo-radiotherapy.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePatient Characteristics\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNumber of patients (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge (years), median (range)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e64.6 (54.5\u0026ndash;74.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;65 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e79 (51.6%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;65 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e74 (48.4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e60 (39.2%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e93 (60.8%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eECOG performance status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e47 (30.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e100 (65.4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e6 (4.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSmoking status\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNever smoker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e105 (68.6%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCurrent or Ex-smoker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e48 (31.4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHistology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAdenocarcinoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e147 (96.1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSquamous\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3 (2.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOthers\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3 (2.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStage at initial diagnosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e23 (15.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12 (7.9%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e19 (12.4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e99 (64.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrevious history of treatments\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCurative surgery\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e47 (30.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDefinitive CCRT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e10 (6.5%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eType of \u003cem\u003eEGFR\u003c/em\u003e mutation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExon 19 deletion\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e77 (50.3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eL858R mutation in exon 21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e71 (46.4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOthers\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e5 (3.3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDistant metastasis at initiation of dacomitinib\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBrain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e69 (45.1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBone\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e56 (36.6%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePleura\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e45 (29.4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAdrenal gland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e10 (6.5%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLiver\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e7 (4.6%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAt the initiation of dacomitinib, 69 patients (45.1%) presented with concurrent brain metastasis, while bone metastasis, pleural metastasis, liver metastasis, and adrenal metastasis were observed in 56 (36.6%), 45 (29.4%), 10 (6.5%), and 7 (4.6%) patients, respectively.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eEfficacy of dacomitinib\u003c/h2\u003e \u003cp\u003eThe data lock was performed on April 30th, 2023. At the time of data lock, with 16.9 months of median follow-up duration (range: 5.9\u0026ndash;27.9), 67 patients experienced a PFS event, while 73 patients continued dacomitinib. The median number of cycles of dacomitinib was 13 (range: 2\u0026ndash;24). Out of the 153 patients receiving dacomitinib, one patient achieved CR (0.7%), while 128 achieved PR (83.7%), resulting in an ORR of 84.3% (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). The median PFS was 16.7 months (95% CI; 14.4\u0026ndash;25.2) in total population (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). The median OS was not reached, with a 24-month OS rate of 83.9% (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). Among patients with exon 19 deletion, the median PFS was 18.1 months (95% CI: 14.5\u0026ndash;not reached), while among those with the L858R mutation in exon 21, the median PFS was 15.9 months (95% CI: 12.5\u0026ndash;not reached) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). Among patients with brain metastasis, the median PFS was 14.5 months (95% CI: 11.2\u0026ndash;20.0), whereas the median PFS was 20.2 months in those without brain metastasis (95% CI: 17.5\u0026ndash;not reached), indicating a longer PFS in the absence of brain metastasis (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.037) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eObjective response to dacomitinib. PFS, Progression-free survival.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTreatment response\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNumber of patients (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo. of cycles, median (range)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13 (2\u0026ndash;24)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComplete response\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePartial response\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e128 (83.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStable disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11 (7.2%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eProgressive disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (3.9%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUnknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7 (4.6%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOverall objective response rate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e129 (84.3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOverall disease control rate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e140 (91.5%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eProportion overall PFS at 12 months\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e48.4%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eSafety profile\u003c/h2\u003e \u003cp\u003eOut of the total 153 patients, 94.1% reported at least one adverse event, while 11 patients (7.2%) reported adverse events of grade 3 or higher. Grade 4 adverse event was not reported. The most commonly reported adverse events were rash, diarrhea, and mucositis (51.0%, 49.0%, and 40.5% respectively) (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAdverse events and dose reduction of dacomitinib.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAdverse Events\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAny grade\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGrade\u0026thinsp;\u0026ge;\u0026thinsp;3\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDiarrhea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e75 (49.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3 (2.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eParonychia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e60 (39.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDermatitis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e45 (29.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1 (0.7%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRash\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e78 (51.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7 (4.6%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOral mucositis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e62 (40.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNausea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3 (2.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFatigue\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e6 (3.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIncreased AST/ALT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1 (0.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePneumonitis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFinal reduced dose owing to adverse events\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo dose reduction\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e22 (14.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDose reduction\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e131 (85.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e30 mg per day\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e75 (49.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e15 mg per day\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e56 (36.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePermanent discontinuation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13 (8.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTemporary interruption\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e37 (24.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eOne hundred and fifty patients started on a once-daily dose of 45 mg of dacomitinib, while three patients started dacomitinib with a dosage of 30 mg. Dose reductions owing to adverse events occurred in 131 (85.6%) patients. The lowest dacomitinib dose was 30 mg once daily in 75 patients (49.0%) and 15 mg once daily in 56 patients (36.6%). Moreover, it took a median time of 1.2 months to achieve a dose reduction of 30 mg, and 4.3 months to 15 mg. Temporary dose interruptions occurred in 37 (24.2%) patients. Thirteen patients (8.5%) permanently discontinued dacomitinib and changed to other EGFR-TKI owing to intolerable adverse events.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eSubsequential treatment after dacomitinib\u003c/h2\u003e \u003cp\u003eFigure \u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e summarizes the subsequent treatments of patients after dacomitinib as a first-line treatment. Seventy-three patients continued dacomitinib without evidence of disease progression, while 14 patients discontinued dacomitinib for reasons other than disease progression. Among 66 patients who experienced disease progression while on dacomitinib, 22 patients (33.3%) continued dacomitinib under the concept of beyond progression. Among them, lesions associated with disease progression occurred in the brain, bone, and lung in 11, 9, and 3 patients, respectively. Among 11 patients with intracranial progression, 8 patients underwent gamma-knife radiosurgery for the corresponding lesions. At the time of data lock, 6 patients continued dacomitinib beyond disease progression.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThirty-one patients underwent tissue re-biopsy to confirm the acquired resistance mechanism of dacomitinib. Nine patients had the EGFR T790M mutation in exon 20 (T790M), and all of them switched to third-generation EGFR TKIs: 2 patients to osimertinib and 7 to lazertinib. Additional liquid biopsy was performed in 18 patients who did not have T790M on tissue re-biopsy. Three patients had T790M and two of them switched to third-generation EGFR TKIs: 1 to osimertinib and 1 to lazertinib. Fifteen patients were without the T790M mutation either by tissue re-biopsy or liquid biopsy. Three of them were enrolled in a clinical trial for further treatment and remain under observation, while 11 patients received platinum-based cytotoxic chemotherapy (10 received pemetrexed/carboplatin and 1 received gemcitabine/carboplatin). One patient refused further treatment owing to poor performance status.\u003c/p\u003e \u003cp\u003eLiquid biopsy was performed in 25 patients among patients who did not receive tissue re-biopsy. Fifteen patients had T790M and all of them switched to third-generation EGFR TKI; 8 to osimertinib and 7 to lazertinib. Among 12 patients who did not have T790M, 5 patients received cytotoxic chemotherapy (4 received pemetrexed/Carboplatin and 1 received gemcitabine/carboplatin). Others refused further treatment owing to poor performance or were transferred to another hospital.\u003c/p\u003e \u003cp\u003eOverall, T790M was detected in 40.9% of patients who progressed from dacomitinib. In patients who underwent tissue re-biopsy, additional examinations were conducted to identify other resistance mechanisms beyond T790M. C-MET expression was assessed through immunohistochemistry staining using re-biopsy tissue, with positive results observed in 7 patients. No histological transformation to small-cell lung cancer was detected. Additionally, next-generation sequencing (NGS) was conducted in 11 patients, and \u003cem\u003eTP53\u003c/em\u003e mutation was detected in 8 of them.\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this retrospective study, dacomitinib showed a durable efficacy and maintained a manageable safety profile but necessitated dose reduction in the majority of patients in patients with EGFR-mutated NSCLC. For the overall population, ORR was 84.3% and the median PFS was 16.7 months, which was quite superior to the survival results represented in ARCHER 1050\u003csup\u003e8\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe primary differences in baseline characteristics compared to ARCHER 1050 are the presence of brain metastasis and racial composition. Unlike ARCHER 1050, which demonstrated a relatively diverse racial distribution with 75% Asian, 25% White, and less than 1% Black participants, this retrospective study was only included Asian in South Korea. Furthermore, ARCHER 1050 excluded patients with brain metastasis, while 45.1% of patients had brain metastasis at the initiation of dacomitinib in this study. Survival results are superior in this study compared to ARCHER 1050, despite including patients with brain metastasis. The distribution of smoking status and the prevalence of EGFR mutation, including exon 19 deletion and L858R mutation in exon 21 were comparable between this study and ARCHER 1050.\u003c/p\u003e \u003cp\u003eAs mentioned above, the efficacy of dacomitinib in patients with brain metastasis was initially unclear in previous prospective studies. In this study, the inclusion of patients with brain metastasis and survival analysis based on the presence of brain metastasis contributed to obtaining insight regarding this aspect, despite its retrospective nature. The median PFS was 16.7 months despite 45.1% of patients having brain metastasis. Several retrospective studies showed the intracranial efficacy of dacomitinib, with an overall intracranial objective response rate (iORR) of 85%\u003csup\u003e12,13\u003c/sup\u003e. In a previous prospective study involving 30 patients with brain metastasis, dacomitinib demonstrated an iORR of 96.7% and the median PFS was 17.5 months\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn subgroup analysis conducted based on EGFR mutation in ARCHER 1050, dacomitinib demonstrated significantly superior survival efficacy compared to gefitinib in patients harboring L858R mutation in exon 21 (hazard ratio: 0.63, 95% CI; 0.44–0.88). The superior survival efficacy of dacomitinib in patients with the L858R mutation in exon 21 represents a unique feature not observed in other EGFR-TKIs, including afatinib, which belongs to the same generation of EGFR TKIs\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Recent in vitro studies revealed that dacomitinib demonstrates the lowest IC50 values for the L858R mutation in exon 21 (IC50 = 2.6) compared to gefitinib (IC50 = 26), erlotinib (IC50 = 16), afatinib (IC50 = 4), and osimertinib (IC50 = 9). The efficacy of dacomitinib in L858R mutation in exon 21 appears to be linked to these IC50 values\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. Additionally, in FLAURA, subgroup analysis based on EGFR mutation demonstrates relatively limited OS benefit in L858R mutation in the exon 21 subgroup with osimertinib (hazard ratio: 1.0, 95% CI; 0.71–1.40)\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. Dacomitinib may represent a promising treatment option for patients with EGFR-mutant NSCLC harboring L858R mutation in exon 21, when compared to other EGFR TKIs.\u003c/p\u003e \u003cp\u003eThe recommended optimal starting dose for dacomitinib is 45 mg per day in ARCHER 1050. However, women, Asians, and patients with lower body weight tend to reduce the dose\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. In this study, dose reductions were necessary in most patients (85.6%) owing to adverse events. This study also showed that the reduction to 30 mg took a median time of 1.2 months, while further reduction to 15 mg required a median time of 4.3 months. The relatively early implementation of dose reductions can be attributed to the prevailing belief that a generous reduction is preferable and does not compromise efficacy\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. The metabolism of dacomitinib varies individually. In previous study of dacomitinib through plasma concentration, there was no difference among the patients who remained on 45 mg per day, those who had their dose reduced from 45 mg to 30 mg per day, and those who had their dose reduced from 45 mg to 30 mg and then to 15 mg per day. Starting at 45 mg or 30 mg per day and adjusting according to adverse events with close and frequent follow-up is a top-down approach which considered to be optimal\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIt is well-established that T790M mutation in exon 20 occur in 50%-60% of patients treated with EGFR first- or second-generation TKIs\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. The clinical data regarding the resistance mechanism of dacomitinib is still limited. In this study, T790M mutations were observed in 40% of cases, which is consistent with previous data from other first- or second-generation EGFR-TKIs.\u003c/p\u003e \u003cp\u003eThis study had several limitations. The median OS was not reached owing to the relatively short follow-up time. Additionally, the retrospective nature of this study and the small sample size further constrain its findings.\u003c/p\u003e \u003cp\u003eIn conclusion, this study demonstrated a real-world efficacy of dacomitinib in EGFR-mutated NSCLC as a first-line treatment. With a tolerable safety profile and superior survival efficacy compared with previous prospective studies, it is anticipated to be a valuable second-generation EGFR TKI in clinical practice. Additionally, the study highlights its efficacy in patients with brain metastasis, establishing it as one of the viable treatment options for NSCLC patients with brain metastasis.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003cdiv id=\"Sec9\" class=\"Section3\"\u003e \u003c/div\u003e \u003c/div\u003e "},{"header":"Patients and Methods","content":"\u003ch2\u003eStudy participants and study procedure\u003c/h2\u003e\u003cp\u003eThis study included patients with advanced/metastatic EGFR-mutant NSCLC who were administered first-line dacomitinib between January 6th, 2021, and December 9th, 2022 at Samsung Medical Center and St. Vincent’s Hospital. All patients received a dosage of 45 mg of dacomitinib administered once daily in 28-day cycles until they experienced objective disease progression, unacceptable toxicity, or death. A dose reduction to 30 mg or 15 mg was performed when patients experienced grade 2 or higher treatment-related toxicities.\u003c/p\u003e\u003cp\u003e We reviewed the electronic clinical records and extracted data on age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, smoking status, stage at initial diagnosis, histopathology, type of EGFR mutation, and distant metastasis at initiation of dacomitinib.\u003c/p\u003e\u003cp\u003eThis study was approved by the Institutional Review Board of the Samsung Medical Center with a waiver for informed consent (Institutional Review Board no. 2023-05-039).\u003c/p\u003e\u003ch2\u003eStudy endpoints and statistical analysis\u003c/h2\u003e\u003cp\u003eTumor response was evaluated as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Objective response rate (ORR) was defined as the percentage (%) of patients with confirmed CR or PR. PFS was measured from the start of dacomitinib to the date of disease progression using RECIST 1.1 or death from any cause. OS was calculated from the start of dacomitinib to the date of death from any cause. The safety objectives were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.3.\u003c/p\u003e\u003cp\u003eThe categorical and continuous variables were summarized using descriptive statistics. The survival analysis was performed using Kaplan-Meier curves and compared using a log-rank test. All p-values were two-sided and confidence intervals (CI) were at the 95% level, with statistical significance defined as p ≤ 0.05. All statistical analyses were performed using IBM SPSS Statistics 27 and R version 4.3.3.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eCompeting Interests\u003c/h2\u003e \u003cp\u003eThe author(s) declare no competing interests.\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eEthic declarations\u003c/h2\u003e \u003cp\u003e This study was conducted in accordance with the ethical principles of the Declaration of Helsinki (as revised in 2013). This study was approved by the Institutional Review Board at Samsung Medical Center (IRB No. 2023-05-039), and individual consent for this retrospective analysis was waived.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eThe conception and design of the study were carried out by JE Shin, HA Jung, and BY Shim. Administrative support for the study was provided by BY Shim. The study materials or patients were provided by all the authors. The collection and assembly of data were performed by JE Shin and HA Jung. Data analysis and interpretation were conducted by JE Shin and HA Jung. All authors contributed to the writing of the manuscript. The final approval of the manuscript was given by all the authors.\u003c/p\u003e\u003ch2\u003eAcknowledgement\u003c/h2\u003e\u003cp\u003eThis was an independent, investigator-initiated study supported by Pfizer.\u003c/p\u003e\u003ch2\u003eData availability\u003c/h2\u003e \u003cp\u003eThe data analyzed in this study are Samsung Medical center and St. Vincent\u0026rsquo;s Hospital. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors upon reasonable request with the permission of Samsung Medical center and St. Vincent\u0026rsquo;s Hospital.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eSiegel, R. L., Miller, K. D., Fuchs, H. E. \u0026amp; Jemal, A. Cancer Statistics, 2021. \u003cem\u003eCA Cancer J. Clin.\u003c/em\u003e 71, 7\u0026ndash;33. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.3322/caac.21654\u003c/span\u003e\u003cspan address=\"10.3322/caac.21654\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlexander, M., Kim, S. Y. \u0026amp; Cheng, H. Update 2020: Management of Non-Small Cell Lung Cancer. \u003cem\u003eLung\u003c/em\u003e 198, 897\u0026ndash;907. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1007/s00408-020-00407-5\u003c/span\u003e\u003cspan address=\"10.1007/s00408-020-00407-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKawaguchi, T. \u003cem\u003eet al.\u003c/em\u003e Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. J. Clin. Oncol. 34, 2247\u0026ndash;2257. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1200/JCO.2015.64.2322\u003c/span\u003e\u003cspan address=\"10.1200/JCO.2015.64.2322\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S. \u0026amp; Halmos, B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1, 497\u0026ndash;514. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.18632/oncotarget.186\u003c/span\u003e\u003cspan address=\"10.18632/oncotarget.186\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMok, T. S. \u003cem\u003eet al.\u003c/em\u003e Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u0026ndash;957. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1056/NEJMoa0810699\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa0810699\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRosell, R. \u003cem\u003eet al.\u003c/em\u003e Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239\u0026ndash;246. 10.1016/S1470-2045(11)70393-X (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePark, K. \u003cem\u003eet al.\u003c/em\u003e Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17, 577\u0026ndash;589. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/S1470-2045(16)30033-X\u003c/span\u003e\u003cspan address=\"10.1016/S1470-2045(16)30033-X\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWu, Y. L. \u003cem\u003eet al.\u003c/em\u003e Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 1454\u0026ndash;1466. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/S1470-2045(17)30608-3\u003c/span\u003e\u003cspan address=\"10.1016/S1470-2045(17)30608-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSoria, J. C. \u003cem\u003eet al.\u003c/em\u003e Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 378, 113\u0026ndash;125. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1056/NEJMoa1713137\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa1713137\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShirley, M. Dacomitinib: First Global Approval. \u003cem\u003eDrugs\u003c/em\u003e 78, 1947\u0026ndash;1953. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1007/s40265-018-1028-x\u003c/span\u003e\u003cspan address=\"10.1007/s40265-018-1028-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYu, H. A. \u0026amp; Riely, G. J. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J. Natl. Compr. Canc. Netw. 11, 161\u0026ndash;169. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.6004/jnccn.2013.0024\u003c/span\u003e\u003cspan address=\"10.6004/jnccn.2013.0024\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeng, W. \u003cem\u003eet al.\u003c/em\u003e Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report. Lung Cancer 152, 66\u0026ndash;70. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/j.lungcan.2020.12.008\u003c/span\u003e\u003cspan address=\"10.1016/j.lungcan.2020.12.008\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, J. \u003cem\u003eet al.\u003c/em\u003e Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. Thorac. Cancer 12, 3407\u0026ndash;3415. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1111/1759-7714.14222\u003c/span\u003e\u003cspan address=\"10.1111/1759-7714.14222\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJung, H. A. \u003cem\u003eet al.\u003c/em\u003e Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study. ESMO Open 8, 102068. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/j.esmoop.2023.102068\u003c/span\u003e\u003cspan address=\"10.1016/j.esmoop.2023.102068\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKobayashi, Y. \u0026amp; Mitsudomi, T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 107, 1179\u0026ndash;1186. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1111/cas.12996\u003c/span\u003e\u003cspan address=\"10.1111/cas.12996\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRamalingam, S. S. \u003cem\u003eet al.\u003c/em\u003e Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N. Engl. J. Med. 382, 41\u0026ndash;50. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1056/NEJMoa1913662\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa1913662\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCorral, J. \u003cem\u003eet al.\u003c/em\u003e Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 15, 2795\u0026ndash;2805. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.2217/fon-2019-0299\u003c/span\u003e\u003cspan address=\"10.2217/fon-2019-0299\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTan, A. C. \u0026amp; Tan, D. S. W. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J. Clin. Oncol. 40, 611\u0026ndash;625. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1200/JCO.21.01626\u003c/span\u003e\u003cspan address=\"10.1200/JCO.21.01626\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2022).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Epidermal growth factor receptor (EGFR) mutant Non-small cell lung cancer (NSCLC), Dacomitinib, Real-world data","lastPublishedDoi":"10.21203/rs.3.rs-4671317/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4671317/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eDacomitinib demonstrated superior survival benefit compared to gefitinib as a first-line treatment in non-small cell lung cancer (NSCLC) patients with common EGFR mutations through ARCHER 1050. However, there is limited real-world data concerning its efficacy and safety.\u003c/p\u003e \u003cp\u003eThis study included patients with EGFR-mutant NSCLC who received dacomitinib as a first-line treatment between January 2021 and December 2022 at Samsung Medical Center and St. Vincent\u0026rsquo;s Hospital. This study assessed the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), safety profile of dacomitinib, and subsequent treatments after dacomitinib failure.\u003c/p\u003e \u003cp\u003eIn total, 153 patients were included in this study. Exon 19 deletion was observed in 50.3% of patients, while the L858R mutation in exon 21 was observed in 46.4% of patients. 45.1% of patients had brain metastasis. The ORR was 84.3%. The median follow-up duration was 16.9 months, with a median PFS of 16.7 months (95% CI, 14.4 to 25.2). Based on the type of EGFR mutation, the median PFS was 18.1 months (95% CI, 14.5 to NE) in patients with exon 19 deletion, and 15.9 months (95% CI, 12.5 to NE) in patients with L858R mutation. Grade 3 or higher adverse events were observed in 7.2% of patients. Initially administered at a dose of 45 mg, dose reduction was necessary for 85.6% of patients, with a final dosage of 30 mg in 49.0% and 15 mg in 36.6% of cases. Out of the 60 patients who experienced disease progression, 31 underwent tissue re-biopsy and 25 underwent liquid biopsy. Overall, T790M mutation was detected in 40.9% of patients who progressed after dacomitinib.\u003c/p\u003e \u003cp\u003eThe survival benefit of dacomitinib has been demonstrated, indicating its promising efficacy in a real-world setting. The detection rate of the T790M mutation after dacomitinib treatment failure was comparable to that of other second-generation EGFR-TKIs.\u003c/p\u003e","manuscriptTitle":"Dacomitinib as first-line treatment for patients with EGFR-mutant non-small- cell lung cancer: Real-world data and Insights","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-07-29 21:09:04","doi":"10.21203/rs.3.rs-4671317/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-09-25T06:06:28+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-09-23T10:07:53+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"59819691068581047221196288255859478429","date":"2024-09-18T13:31:29+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-08-11T01:45:44+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"160107731288403015120637493690916475485","date":"2024-08-09T14:47:59+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-07-04T06:25:35+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-07-04T06:15:42+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2024-07-04T06:10:19+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-07-04T06:08:37+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2024-07-02T04:18:10+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"c4890058-46c3-43fc-830b-7b59504d9d1c","owner":[],"postedDate":"July 29th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":35062183,"name":"Biological sciences/Cancer/Lung cancer"},{"id":35062184,"name":"Health sciences/Oncology/Cancer/Cancer therapy"}],"tags":[],"updatedAt":"2025-02-10T16:01:23+00:00","versionOfRecord":{"articleIdentity":"rs-4671317","link":"https://doi.org/10.1038/s41598-024-81704-4","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2025-02-07 15:57:22","publishedOnDateReadable":"February 7th, 2025"},"versionCreatedAt":"2024-07-29 21:09:04","video":"","vorDoi":"10.1038/s41598-024-81704-4","vorDoiUrl":"https://doi.org/10.1038/s41598-024-81704-4","workflowStages":[]},"version":"v1","identity":"rs-4671317","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4671317","identity":"rs-4671317","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}